Clinical Trials Logo

Clinical Trial Summary

To determine the safety and tolerability of galunisertib when combined with Stereotactic Body Radiotherapy (SBRT) (hypofractionated radiation).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02906397
Study type Interventional
Source Abramson Cancer Center of the University of Pennsylvania
Contact
Status Completed
Phase Phase 1
Start date March 30, 2017
Completion date July 21, 2021

See also
  Status Clinical Trial Phase
Terminated NCT04985136 - A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) Phase 3
Recruiting NCT02509169 - Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma Phase 2
Active, not recruiting NCT04723004 - Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC Phase 3
Completed NCT02814461 - The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC Phase 1
Not yet recruiting NCT04344158 - A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) Phase 3
Active, not recruiting NCT04523493 - Phase III Study of Toripalimab(JS001) Combined With Lenvatinib for Advanced HCC Phase 3
Terminated NCT05375604 - A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC) Phase 1
Terminated NCT01101906 - A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC Phase 2
Recruiting NCT05862181 - The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma
Not yet recruiting NCT06309485 - Phase 2 Study of WGI-0301 in Combination With Sorafenib for Advanced HCC Phase 2
Terminated NCT04212221 - MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients Phase 1/Phase 2
Active, not recruiting NCT04605796 - A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC) Phase 2